Targeting estrogen receptor improves progression-free survival in advanced breast cancer

(European Society for Medical Oncology) Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen.